|This Slide: #35 of 83|
Slide #35. Retrophin — Kyalin Biosciences
Retrophin, Inc. (OTCQB:RTRX) today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions. Its lead product is an optimized intranasal delivery form of carbetocin, a synthetic analog of the naturally occurring peptide hormone, oxytocin. The deal is scheduled to close by year-end.
Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co.'s commercialized products include Chenodal (chenodiol tablets) for the treatment of radiolucent stones in well-opacifying gallbladders in patients; Cholbam (cholic acid capsules), a treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC (tiopronin), a treatment for cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Open the RTRX Page at The Online Investor »
Strong Buy (3.75 out of 4)